Keywords: idec, regains, rights, radioimmunotherapy, genentech, returned, marketing
IDEC Regains Rights To Radioimmunotherapy
Article | 16 October 1997
- Genentech has returned marketing rights to IDEC Pharmaceuticalsfor IDEC-Y2B8, a radioimmunotherapy product being investigated for the treatment of relapsed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
